Stockscreener 앱 받기
21.30
1.92%
0.438
Arcutis Biotherapeutics Inc 주식(ARQT)의 최신 뉴스
ARQT News | ARCUTIS BIOTHERAPEUTICS INC (NASDAQ:ARQT) - ChartMill
Arcutis Biotherapeutics (ARQT) Price Target Increased by 32.62% to 31.62 - MSN
How (ARQT) Movements Inform Risk Allocation Models - Stock Traders Daily
Number of shareholders of Arcutis Biotherapeutics, Inc. – NASDAQ:ARQT - TradingView
Arcutis Biotherapeutics: The Dermatology Platform Is Starting To Compound (NASDAQ:ARQT) - Seeking Alpha
Arcutis Biotherapeutics, Inc.Common stock (NQ: ARQT - FinancialContent
Arcutis Biotherapeutics SVP CFO Latha Vairavan sells $9,156 in stock. - Investing.com UK
Arcutis EVP, CMO Burnett sells $4,673 in common stock - Investing.com UK
Arcutis Biotherapeutics SVP CFO Latha Vairavan sells $9,156 in stock. By Investing.com - Investing.com Nigeria
Arcutis EVP, CMO Burnett sells $4,673 in common stock By Investing.com - Investing.com South Africa
Arcutis (ARQT) CFO tax-related sale of 435 shares after RSU vesting - Stock Titan
Arcutis Biotherapeutics (ARQT) officer sells 222 shares to cover RSU tax - Stock Titan
Arcutis Q1 2026 slides: revenue surges 65% amid expansion push By Investing.com - Investing.com Nigeria
Arcutis Q1 2026 slides: revenue surges 65% amid expansion push - Investing.com
Earnings call transcript: Arcutis Biotherapeutics Q1 2026 misses EPS expectations By Investing.com - Investing.com South Africa
Earnings call transcript: Arcutis Biotherapeutics Q1 2026 misses EPS expectations - Investing.com Nigeria
State Street (NYSE: STT) holds 6.30M shares of Arcutis (5.1%) - Stock Titan
Arcutis Biotherapeutics (ARQT) Form 144: Patrick Burnett reports share dispositions - Stock Titan
Arcutis Biotherapeutics (ARQT) Form 144 lists 435 vested shares for resale - Stock Titan
H.C. Wainwright Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $34 - Moomoo
Arcutis Earnings Call Signals Momentum Amid Headwinds - TipRanks
FDA Approval for ZORYVE issued to ARCUTIS BIOTHERAPEUTICS INC - Quantisnow
Arcutis outlines $480M-$495M 2026 revenue guidance while expanding ZORYVE sales teams - MSN
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Arcutis Biotherapeutics (ARQT) Is Down 11.0% After Strong Q1 And sNDA For ZORYVE Expansion - Yahoo Finance
40 new Arcutis hires receive stock units and options under Nasdaq rule - Stock Titan
Prudential Financial (ARQT) reports 5.30M-share stake; Jennison holds 4.98M - Stock Titan
ARQT SEC FilingsArcutis Biotherapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Arcutis Biotherapeutics (ARQT) Reports Strong Q1 2026 Earnings w - GuruFocus
ARQT Reiterates by Needham -- Price Target Maintained at $36.00 - GuruFocus
TD Cowen Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $35 - Moomoo
A Quick Look at Today's Ratings for Arcutis Biotherapeutics(ARQT.US), With a Forecast Between $34 to $36 - Moomoo
Arcutis Biotherapeutics, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Needham Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $36 - Moomoo
Arcutis Biotherapeutics Reaffirmed at Buy as Growth Outlook Strengthens; $36 Price Target Maintained - TipRanks
Arcutis Biotherapeutics CMO sells $16,149 in shares By Investing.com - Investing.com Australia
Arcutis Biotherapeutics, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:ARQT) 2026-05-07 - Seeking Alpha
Arcutis Biotherapeutics EVP Masaru Matsuda sells $192k in stock By Investing.com - Investing.com South Africa
Arcutis Biotherapeutics SVP CFO Latha Vairavan sells $31,661 in stock By Investing.com - Investing.com Australia
Arcutis Biotherapeutics EVP Masaru Matsuda sells $192k in stock - Investing.com UK
2.25%
0.46%
자본화:
|
볼륨(24시간):